MURA Mural Oncology plc

Nasdaq


$ 2.09 $ 0.01 (0.48 %)    

Monday, 10-Nov-2025 15:59:56 EST
QQQ $ 623.82 $ 4.38 (0.71 %)
DIA $ 473.95 $ 1.94 (0.41 %)
SPY $ 681.69 $ 4.15 (0.61 %)
TLT $ 89.46 $ 0.06 (0.07 %)
GLD $ 380.15 $ 2.40 (0.64 %)
$ 2.1
$ 2.08
$ 2.07 x 168
$ 2.13 x 31
-- - --
$ 0.95 - $ 4.74
71,743
na
36.42M
$ -0.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-11-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-26-2024 12-31-2023 10-K
9 12-14-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously a...

Core News & Articles

Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1....

 mural-oncology-shares-surge-as-company-explores-strategic-alternatives-whats-going-on

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinu...

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado maintains Mural Oncology (NASDAQ:MURA) with a Buy and lowers the price targ...

 mural-oncologys-ovarian-cancer-combo-drug-trial-disappoints-stock-plunges

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for...

Core News & Articles

Jones Trading analyst Soumit Roy downgrades Mural Oncology (NASDAQ:MURA) from Buy to Hold.

Core News & Articles

In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with p...

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:MURA) with a Buy and maintains $18 price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION